AbbVie Signs Patent License with Momenta for Humira Biosimilar
AbbVie will grant Momenta license to launch a biosimilar to AbbVie’s Humira.
On Nov. 6, 2018, AbbVie announced patent license agreements with Momenta over its proposed biosimilar adalimumab product.
Under the terms of the agreements, AbbVie will grant Momenta a non-exclusive license on specified dates to AbbVie's intellectual property relating to Humira (adalimumab) in the United States and in other countries in which AbbVie has intellectual property. Momenta will pay royalties to AbbVie for licensing its Humira patents and acknowledges the validity of the licensed patents. AbbVie will make no payments to Momenta. Other terms of the agreement were not disclosed.
Momenta's US license will begin on Nov. 20, 2023 and will not be accelerated by the entry of companies who have already taken a license. In the European Union, Momenta can launch upon approval from the European Medicines Agency.
AbbVie's previously announced US dates for patent licenses are:
- Amgen-Jan. 31, 2023
- Samsung Bioepis-June 30, 2023
- Mylan-July 31, 2023
- Fresenius Kabi-Sept. 30, 2023
- Sandoz-Sept. 30, 2023.
Source: AbbVie
